Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IVA 
Inventiva Sa (IVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/18/2025: IVA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.88
1 Year Target Price $15.88
| 6 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.54% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 557.31M USD | Price to earnings Ratio - | 1Y Target Price 15.88 |
Price to earnings Ratio - | 1Y Target Price 15.88 | ||
Volume (30-day avg) 7 | Beta 0.78 | 52 Weeks Range 2.11 - 7.98 | Updated Date 11/14/2025 |
52 Weeks Range 2.11 - 7.98 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-21 | When - | Estimate -0.29 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -991.89% |
Management Effectiveness
Return on Assets (TTM) -56.77% | Return on Equity (TTM) -1642.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 472303254 | Price to Sales(TTM) 34.98 |
Enterprise Value 472303254 | Price to Sales(TTM) 34.98 | ||
Enterprise Value to Revenue 29.84 | Enterprise Value to EBITDA -1.34 | Shares Outstanding 145891723 | Shares Floating 76913084 |
Shares Outstanding 145891723 | Shares Floating 76913084 | ||
Percent Insiders - | Percent Institutions 5.18 |
Upturn AI SWOT
Inventiva Sa
Company Overview
History and Background
Inventiva SA is a French biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical need, particularly in the areas of NASH (non-alcoholic steatohepatitis) and other metabolic diseases. Founded in 2012.
Core Business Areas
- NASH Drug Development: Inventiva's primary focus is the development and commercialization of lanifibranor, a pan-PPAR agonist, for the treatment of NASH.
- Other Metabolic Diseases: Inventiva is exploring other applications for its PPAR agonist platform in other metabolic disorders.
Leadership and Structure
Frederic Cren is the Chairman and CEO. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- Lanifibranor: Lanifibranor is Inventiva's lead product candidate for the treatment of NASH. While still in clinical development, it aims to address liver inflammation and fibrosis. Market share is currently N/A as it is not yet approved. Competitors include Madrigal Pharmaceuticals (Resmetirom) and Viking Therapeutics (VK2809), and other NASH treatments in development.
Market Dynamics
Industry Overview
The NASH market is a large and rapidly growing market due to the increasing prevalence of obesity and diabetes. There is a significant unmet need for effective therapies.
Positioning
Inventiva is positioned as a company with a potentially differentiated NASH therapy based on its pan-PPAR agonist mechanism. It aims to compete with other companies developing NASH treatments.
Total Addressable Market (TAM)
The global NASH market is projected to reach tens of billions of dollars. Inventiva aims to capture a significant share of this market with lanifibranor.
Upturn SWOT Analysis
Strengths
- Pan-PPAR agonist mechanism (potentially more effective than single PPAR agonists)
- Clinical trial data showing efficacy in NASH patients
- Experienced management team
Weaknesses
- Lanifibranor not yet approved (regulatory risk)
- High cash burn rate (requires funding)
- Smaller company compared to competitors
Opportunities
- Potential approval of lanifibranor for NASH
- Expansion into other metabolic diseases
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other NASH therapies
- Patent expiration
Competitors and Market Share
Key Competitors
- GILD
- MRTX
- VKTX
Competitive Landscape
Inventiva's advantage lies in its pan-PPAR agonist mechanism, but faces competition from larger pharmaceutical companies with more resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is still in the development phase.
Future Projections: Future growth depends on the approval and commercialization of lanifibranor. Analyst estimates vary widely depending on the perceived likelihood of approval and market uptake.
Recent Initiatives: Focus on completing Phase 3 clinical trials for lanifibranor and preparing for regulatory submissions.
Summary
Inventiva SA is a clinical-stage biopharmaceutical company focused on NASH, with lanifibranor being its lead drug. The company's success hinges on the approval and commercial uptake of lanifibranor. However, it faces regulatory and competitive risks. While their pan-PPAR approach is promising, they require financing. Clinical trial outcomes will ultimately determine its viability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Inventiva SA's website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be complete or accurate. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inventiva Sa
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-07-10 | CEO & Director Mr. Andrew Obenshain | ||
Sector Healthcare | Industry Biotechnology | Full time employees 84 | Website https://inventivapharma.com |
Full time employees 84 | Website https://inventivapharma.com | ||
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.